Compare Citius Pharmaceuticals Inc (CTXR) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.14. The key difference: T-Rex 2X Inverse MSTR Daily Target ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | MSTZ | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $27.92 |
52-Week Low | $0.53 | $3.12 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MSTZ trades at $13.16, up 5.07% today with a bullish technical signal from moving averages. The stock shows neutral oscillators but strong momentum indicators. Key support sits at $13 with resistance at $14. Recent ETF performance news highlights momentum strategies but lacks direct MSTZ coverage.
Outlook hinges on undisclosed fundamentals; current technical strength suggests near-term upside if $14 resistance breaks. Risks include absence of visible financial metrics and reliance on broader market trends. Investors need earnings clarity for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
